These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 22050625)

  • 1. Cardiomyocytes generated from CPVTD307H patients are arrhythmogenic in response to β-adrenergic stimulation.
    Novak A; Barad L; Zeevi-Levin N; Shick R; Shtrichman R; Lorber A; Itskovitz-Eldor J; Binah O
    J Cell Mol Med; 2012 Mar; 16(3):468-82. PubMed ID: 22050625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional abnormalities in iPSC-derived cardiomyocytes generated from CPVT1 and CPVT2 patients carrying ryanodine or calsequestrin mutations.
    Novak A; Barad L; Lorber A; Gherghiceanu M; Reiter I; Eisen B; Eldor L; Itskovitz-Eldor J; Eldar M; Arad M; Binah O
    J Cell Mol Med; 2015 Aug; 19(8):2006-18. PubMed ID: 26153920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A mutation in calsequestrin, CASQ2D307H, impairs Sarcoplasmic Reticulum Ca2+ handling and causes complex ventricular arrhythmias in mice.
    Dirksen WP; Lacombe VA; Chi M; Kalyanasundaram A; Viatchenko-Karpinski S; Terentyev D; Zhou Z; Vedamoorthyrao S; Li N; Chiamvimonvat N; Carnes CA; Franzini-Armstrong C; Györke S; Periasamy M
    Cardiovasc Res; 2007 Jul; 75(1):69-78. PubMed ID: 17449018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calsequestrin mutation and catecholaminergic polymorphic ventricular tachycardia: a simulation study of cellular mechanism.
    Faber GM; Rudy Y
    Cardiovasc Res; 2007 Jul; 75(1):79-88. PubMed ID: 17531962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell model of catecholaminergic polymorphic ventricular tachycardia reveals early and delayed afterdepolarizations.
    Kujala K; Paavola J; Lahti A; Larsson K; Pekkanen-Mattila M; Viitasalo M; Lahtinen AM; Toivonen L; Kontula K; Swan H; Laine M; Silvennoinen O; Aalto-Setälä K
    PLoS One; 2012; 7(9):e44660. PubMed ID: 22962621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-Specific Human Induced Pluripotent Stem Cell Model Assessed with Electrical Pacing Validates S107 as a Potential Therapeutic Agent for Catecholaminergic Polymorphic Ventricular Tachycardia.
    Sasaki K; Makiyama T; Yoshida Y; Wuriyanghai Y; Kamakura T; Nishiuchi S; Hayano M; Harita T; Yamamoto Y; Kohjitani H; Hirose S; Chen J; Kawamura M; Ohno S; Itoh H; Takeuchi A; Matsuoka S; Miura M; Sumitomo N; Horie M; Yamanaka S; Kimura T
    PLoS One; 2016; 11(10):e0164795. PubMed ID: 27764147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adeno-associated virus-mediated CASQ2 delivery rescues phenotypic alterations in a patient-specific model of recessive catecholaminergic polymorphic ventricular tachycardia.
    Lodola F; Morone D; Denegri M; Bongianino R; Nakahama H; Rutigliano L; Gosetti R; Rizzo G; Vollero A; Buonocore M; Napolitano C; Condorelli G; Priori SG; Di Pasquale E
    Cell Death Dis; 2016 Oct; 7(10):e2393. PubMed ID: 27711080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A human pluripotent stem cell model of catecholaminergic polymorphic ventricular tachycardia recapitulates patient-specific drug responses.
    Preininger MK; Jha R; Maxwell JT; Wu Q; Singh M; Wang B; Dalal A; Mceachin ZT; Rossoll W; Hales CM; Fischbach PS; Wagner MB; Xu C
    Dis Model Mech; 2016 Sep; 9(9):927-39. PubMed ID: 27491078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calsequestrin 2 (CASQ2) mutations increase expression of calreticulin and ryanodine receptors, causing catecholaminergic polymorphic ventricular tachycardia.
    Song L; Alcalai R; Arad M; Wolf CM; Toka O; Conner DA; Berul CI; Eldar M; Seidman CE; Seidman JG
    J Clin Invest; 2007 Jul; 117(7):1814-23. PubMed ID: 17607358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormal calcium signaling and sudden cardiac death associated with mutation of calsequestrin.
    Viatchenko-Karpinski S; Terentyev D; Györke I; Terentyeva R; Volpe P; Priori SG; Napolitano C; Nori A; Williams SC; Györke S
    Circ Res; 2004 Mar; 94(4):471-7. PubMed ID: 14715535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the first induced pluripotent stem cell line generated from a patient with autosomal dominant catecholaminergic polymorphic ventricular tachycardia due to a heterozygous mutation in cardiac calsequestrin-2.
    Ross S; Holliday M; Lim S; Semsarian C
    Stem Cell Res; 2019 May; 37():101450. PubMed ID: 31039485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-Specific Drug Screening Using a Human Induced Pluripotent Stem Cell Model of Catecholaminergic Polymorphic Ventricular Tachycardia Type 2.
    Maizels L; Huber I; Arbel G; Tijsen AJ; Gepstein A; Khoury A; Gepstein L
    Circ Arrhythm Electrophysiol; 2017 Jun; 10(6):. PubMed ID: 28630169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells.
    Itzhaki I; Maizels L; Huber I; Gepstein A; Arbel G; Caspi O; Miller L; Belhassen B; Nof E; Glikson M; Gepstein L
    J Am Coll Cardiol; 2012 Sep; 60(11):990-1000. PubMed ID: 22749309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional consequences of stably expressing a mutant calsequestrin (CASQ2D307H) in the CASQ2 null background.
    Kalyanasundaram A; Viatchenko-Karpinski S; Belevych AE; Lacombe VA; Hwang HS; Knollmann BC; Gyorke S; Periasamy M
    Am J Physiol Heart Circ Physiol; 2012 Jan; 302(1):H253-61. PubMed ID: 21984545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of ventricular arrhythmia and calcium dysregulation in a catecholaminergic polymorphic ventricular tachycardia mouse model carrying calsequestrin-2 mutation.
    Alcalai R; Wakimoto H; Arad M; Planer D; Konno T; Wang L; Seidman JG; Seidman CE; Berul CI
    J Cardiovasc Electrophysiol; 2011 Mar; 22(3):316-24. PubMed ID: 20807279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene Transfer of Engineered Calmodulin Alleviates Ventricular Arrhythmias in a Calsequestrin-Associated Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia.
    Liu B; Walton SD; Ho HT; Belevych AE; Tikunova SB; Bonilla I; Shettigar V; Knollmann BC; Priori SG; Volpe P; Radwański PB; Davis JP; Györke S
    J Am Heart Assoc; 2018 May; 7(10):. PubMed ID: 29720499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of mutant protein level in autosomal recessive catecholamine dependent polymorphic ventricular tachycardia (CPVT2).
    Katz G; Shainberg A; Hochhauser E; Kurtzwald-Josefson E; Issac A; El-Ani D; Aravot D; Afek A; Seidman JG; Seidman CE; Eldar M; Arad M
    Biochem Pharmacol; 2013 Dec; 86(11):1576-83. PubMed ID: 24070655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired Dynamic Sarcoplasmic Reticulum Ca Buffering in Autosomal Dominant CPVT2.
    Wleklinski MJ; Kryshtal DO; Kim K; Parikh SS; Blackwell DJ; Marty I; Iyer VR; Knollmann BC
    Circ Res; 2022 Sep; 131(8):673-686. PubMed ID: 36102198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling Catecholaminergic Polymorphic Ventricular Tachycardia using Induced Pluripotent Stem Cell-derived Cardiomyocytes.
    Novak A; Lorber A; Itskovitz-Eldor J; Binah O
    Rambam Maimonides Med J; 2012 Jul; 3(3):e0015. PubMed ID: 23908839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation-specific differences in arrhythmias and drug responses in CPVT patients: simultaneous patch clamp and video imaging of iPSC derived cardiomyocytes.
    Pölönen RP; Swan H; Aalto-Setälä K
    Mol Biol Rep; 2020 Feb; 47(2):1067-1077. PubMed ID: 31786768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.